Trinity Biotech PLC
IDA Business Park
Bray, Co
Wicklow
Tel: 353-1-276-9800-Or-800-603-8076
Fax: +353-1-276-9888
Website: http://www.trinitybiotech.com/
191 articles about Trinity Biotech PLC
-
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
-
Trinity Biotech Announces Quarter 4 and Fiscal Year 2021 Financial Results
4/11/2022
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2021 and fiscal year 2021.
-
Trinity Biotech Announces A $45 Million Strategic Investment And Partnership With The MiCo Group of South Korea
4/11/2022
Trinity Biotech plc today announced a $45 million strategic investment and partnership with MiCo Ltd (“MiCo”). MiCo, a KOSDAQ-listed and Korea-based company, is engaged in the biomedical business through its affiliate MiCo BioMed, in addition to providing cutting-edge technology driven solutions in the semi-conductor and green energy sectors.
-
Biopharma and life sciences companies from across the globe provide updates to their pipelines and businesses.
-
Trinity Biotech Announces the World Health Organisation Approval Of TrinScreen™ HIV
2/14/2022
Trinity Biotech plc (Nasdaq: TRIB) has received approval for its new HIV screening product, TrinScreen™ HIV, from the World Health Organisation (WHO).
-
Trinity Biotech Announces The Successful Closing of its Debt Refinancing
1/27/2022
Trinity Biotech plc today announced that it has closed its recently announced refinancing.
-
Trinity Biotech Announces Q3 2021 Results, the Entry Into a $81,250,000 Loan Facility to Refinance the Company’s Exchangeable Senior Notes and Agreements To Repurchase Outstanding Exchangeable Senior Notes
12/15/2021
Trinity Biotech plc announced results for the quarter ended September 30, 2021, the entry into a $81.25million loan facility to refinance the existing $99.9million of exchangeable senior notes issued by the Company’s subsidiary, Trinity Biotech Investment Limited, and exchange agreements for over 99.7% of the outstanding Notes, all subject to certain conditions precedent.
-
Trinity Biotech Announces Results for Q2, 2021
9/9/2021
Trinity Biotech plc today announced results for the quarter ended June 30, 2021.
-
Trinity Biotech Provides A Business Development Update For Q2 2021
7/16/2021
Trinity Biotech plc (Nasdaq: TRIB) provides a business development update for Q2 2021.
-
Trinity Biotech Announces Results for Q1, 2021
5/25/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2021. Quarter 1 Results Total revenues for Q1, 2021 were $25.6m which compares to $21.2m in Q1, 2020, an increase of 20.9% and which were broken down as follows: 2020 Quarter 1 2021 Quarter 1 Increase/ (decrease)
-
Trinity Biotech plc to Announce First Quarter Fiscal Year 2021 Financial ResultsConference Call Scheduled for May 25, 2021 at 11:00 am EASTERN
5/19/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the first quarter fiscal year 2021 on Tuesday, May 25, 2021.
-
Trinity Biotech Announces Quarter 4 and Fiscal Year 2020 Financial Results
3/25/2021
Trinity Biotech plc, a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced results for the quarter ended December 31, 2020 and fiscal year 2020.
-
Trinity Biotech plc to Announce Fourth Quarter and Fiscal Year 2020 Financial ResultsConference Call Scheduled for March 25, 2021 at 11:00 am EASTERN
3/23/2021
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2020 on Thursday, March 25, 2021.
-
Trinity Biotech Announces Results for Q3, 2020
11/17/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended September 30, 2020. Quarter 3 Results Total revenues for Q3, 2020 were $32.0m, which is broken down as follows: 2019 Quarter 3 2020 Quarter 3 Change US$’000 US$’000 % Point-of-Care 3,880 2,065 (46.8)% Cl
-
Trinity Biotech plc to Announce Third Quarter 2020 Financial ResultsConference Call Scheduled for November 17, 2020 at 11:00 am EASTERN
10/29/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the third quarter 2020 on Tuesday, November 17, 2020. The Company has scheduled a conference call for that same day, Tuesday, November 17, 2020 at 11:00am ET (4:00pm GMT) to discuss the results of the quarter. Interested parties can access the call by dialing: US Tol
-
Trinity Biotech Announces Results for Q2, 2020
8/25/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended June 30, 2020.
-
Trinity Biotech announces EUA submission for Covid-19 ELISA Antibody test
8/20/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets announced that it has filed its submission for an Emergency Use Authorization (EUA) for its Covid-19 IgG ELISA antibody test with the FDA. This test will determine which individuals within the population have been exposed to the SARS-CoV-2 virus. The transfer of production to our facility in Jame
-
Trinity Biotech plc to Announce Second Quarter 2020 Financial ResultsConference Call Scheduled for August 25, 2020 at 11:00am EASTERN
8/18/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter 2020 on Tuesday, August 25, 2020. The Company has scheduled a conference call for that same day, Tuesday, August 25, 2020 at 11:00am ET (4:00pm BST) to discuss the results of the quarter. Interested parties can access the call by dialing:
-
Trinity Biotech subsidiary, Primus Corporation Receives FDA Warning Letter
8/17/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, announced that its subsidiary Primus Corporation has received a warning letter from the U.S. Food and Drug Administration (FDA) following an inspection of its Kansas City, Missouri manufacturing facility that took place in January 2020. The issues identified in this letter primarily relate to th
-
Trinity Biotech Announces Results for Q1, 2020
5/27/2020
Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2020.